Moreover, resistance to BRAF inhibitors has been associated with increased PD-L1 expression in tumor cells, resulting in PD-1 blockade, a strategy to restore or boost the effectiveness of BRAF inhibition [7,8,9]. The gene discussed is BRAF; the disease is neoplasm.